KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Shares Outstanding (2018 - 2025)

Novartis Ag (NVS) has disclosed Shares Outstanding for 8 consecutive years, with $1.9 billion as the latest value for Q4 2025.

  • Quarterly Shares Outstanding fell 3.39% to $1.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 billion through Dec 2025, down 3.39% year-over-year, with the annual reading at $1.9 billion for FY2025, 3.39% down from the prior year.
  • Shares Outstanding hit $1.9 billion in Q4 2025 for Novartis Ag, down from $2.0 billion in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $2.2 billion in Q4 2021 to a low of $1.9 billion in Q4 2025.
  • Historically, Shares Outstanding has averaged $2.1 billion across 5 years, with a median of $2.0 billion in 2023.
  • Biggest five-year swings in Shares Outstanding: decreased 0.97% in 2021 and later fell 5.16% in 2022.
  • Year by year, Shares Outstanding stood at $2.2 billion in 2021, then dropped by 5.16% to $2.1 billion in 2022, then dropped by 3.57% to $2.0 billion in 2023, then fell by 3.37% to $2.0 billion in 2024, then dropped by 3.39% to $1.9 billion in 2025.
  • Business Quant data shows Shares Outstanding for NVS at $1.9 billion in Q4 2025, $2.0 billion in Q4 2024, and $2.0 billion in Q4 2023.